Trastuzumab deruxtecan (solution)
Trastuzumab deruxtecan is a HER2-targeted ADC linking trastuzumab to deruxtecan, a topoisomerase I inhibitor, via a cleavable tetrapeptide linker. Supplied as a solution, it specifically delivers the payload to HER2-positive cells with stability in circulation and controlled intracellular release.
Key Features and Benefits
-
Targeted Therapy: Directs cytotoxic payload specifically to HER2-positive cells.
-
Cleavable Linker: Ensures plasma stability while enabling intracellular release.
-
Potent Payload: Deruxtecan is a highly active topoisomerase I inhibitor.
-
Solution Formulation: Ready-to-use liquid form simplifies handling in research applications.
-
High Purity: Manufactured to high standards for reproducibility in experimental workflows.
Applications
-
Oncology Research: Studies HER2-targeted drug delivery mechanisms and efficacy.
-
ADC Development: Serves as a model for designing antibody–drug conjugates.
-
Mechanism of Action Studies: Explores HER2 binding, linker stability, and cytotoxic release.
-
Pharmacology: Investigates targeted therapeutics and resistance pathways.
Storage and Handling
-
Storage: Store at recommended temperature (commonly 2–8 °C); protect from light.
-
Handling: Avoid repeated freeze–thaw cycles; use sterile techniques when preparing solutions.
This product provides a clinically validated example of ADC technology, integrating antibody targeting, a cleavable linker, and a potent cytotoxic payload specifically for selective HER2-positive cancer therapy research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.